Dive into the archives.
- Acorda Announces Positive Vote by FDA Advisory Committee for Fampridine-SR
Wed, Oct 14, 2009 * Committee Views Fampridine-SR as Safe, Effective and Clinically Meaningful for Improving Walking in People with Multiple Sclerosis * Conference Call Scheduled for Thursday, October 15 at 8:00 a.m. Eastern Time HAWTHORNE, N.Y.–(Business Wire)– Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced the U.S. Food and Drug Administration (FDA) Peripheral and Central [...]
- Fampridine-SR Receives Priority FDA Review for Walking Drug
Acorda’s shares up sharply on news of FDA priority review for Fampridine-SR in multiple sclerosis Mark Todoruk Shares in Acorda Therapeutics soared as much as 28 percent after the company announced that the FDA accepted its filing of Fampridine-SR (4-aminopyridine) to treat multiple sclerosis, and granted it a priority review. Analyst Phil Nadeau of Cowen [...]
